Introduction: A New Era in Type 1 Diabetes Research

Type 1 diabetes (T1D) is a chronic autoimmune condition in which the immune system mistakenly destroys the insulin-producing beta cells in the pancreas. This leads to lifelong dependence on exogenous insulin, constant blood glucose monitoring, and a significantly increased risk of complications such as cardiovascular disease, kidney failure, and neuropathy. For decades, the standard of care has been management rather than cure. However, the landscape is shifting dramatically, thanks in large part to the relentless efforts of organizations like JDRF (formerly the Juvenile Diabetes Research Foundation). By funding cutting-edge research and fostering collaborations across academia, industry, and regulatory bodies, JDRF has become a driving force behind immune therapies that aim to alter the disease trajectory.

The Role of JDRF in Advancing T1D Immune Therapy

JDRF’s mission is to cure, prevent, and treat T1D and its complications. Over the past several decades, the organization has invested more than $2 billion in research worldwide. A substantial portion of this funding has been directed toward understanding the underlying autoimmune mechanisms of T1D and translating that knowledge into therapies that can modify the immune system’s attack.

Funding Strategic Research Initiatives

JDRF does not simply write checks; it strategically targets high-impact areas. Through its research programs, JDRF has supported the development of immune-modulating drugs, biomarker discovery, beta cell replacement technologies, and prevention strategies. The organization also played a critical role in the creation of the Type 1 Diabetes TrialNet, a network of clinical research centers that conducts studies on the prevention, early detection, and treatment of T1D.

Accelerating Clinical Trials and Regulatory Approvals

JDRF has been instrumental in advancing therapies from bench to bedside. One of the most notable successes is the approval of teplizumab, an anti-CD3 monoclonal antibody that delays the onset of stage 3 T1D in at-risk individuals. In 2022, the U.S. Food and Drug Administration (FDA) approved teplizumab (brand name Tzield) — the first disease-modifying therapy for T1D. JDRF provided key funding for the pivotal clinical trials that led to this landmark approval. This achievement would not have been possible without JDRF’s commitment to taking calculated risks on high-reward research.

Key Scientific Breakthroughs Enabled by JDRF

JDRF’s portfolio spans multiple scientific disciplines, but several breakthroughs stand out as transformative for the field of T1D immune therapy.

Immune-Modulating Therapies: Teaching the Immune System to Stand Down

Traditional immunosuppressive drugs suppress the entire immune system, leaving patients vulnerable to infections and cancers. JDRF-funded researchers have focused on more precise approaches. Teplizumab targets and modifies the activity of T cells, the immune cells responsible for beta cell destruction. By binding to the CD3 receptor on T cells, teplizumab dampens the autoimmune response while preserving overall immune function.

Other immune-modulating agents under investigation include abatacept (CTLA4-Ig), which blocks T cell co-stimulation, and rituximab, an anti-CD20 antibody that depletes B cells. In clinical trials supported by JDRF, these therapies have shown ability to preserve beta cell function, as measured by C-peptide levels, for months to years after treatment. The goal is not to fully reverse the disease but to slow progression and reduce the need for exogenous insulin.

Biomarker Identification: Predicting Who Will Get T1D

To intervene early, you must first know who is at risk. JDRF has funded large-scale studies that have identified autoantibodies against insulin, GAD65, IA-2, and ZnT8 as reliable predictors of T1D onset. Children with two or more of these autoantibodies have a nearly 100% risk of developing clinical T1D within 15 years.

Beyond autoantibodies, JDRF-supported research has uncovered genetic markers, metabolic profiles, and epigenetic changes that refine risk prediction. For example, the TEDDY (The Environmental Determinants of Diabetes in the Young) study, which JDRF helped launch, follows thousands of children from birth to identify environmental triggers of T1D. These biomarkers enable screening programs that can identify candidates for prevention trials, such as the teplizumab studies.

Antigen-Specific Immunotherapy: Precision Tolerance

One of the most elegant approaches to T1D immune therapy is antigen-specific immunotherapy. The idea is to expose the immune system to a specific beta cell antigen (e.g., insulin or GAD65) in a way that induces tolerance rather than attack. JDRF has invested heavily in this area.

For instance, GAD-alum (alum-formulated glutamic acid decarboxylase) has been tested in clinical trials. Although results have been mixed, ongoing studies are exploring optimized dosing, combination with other agents, and earlier intervention. Another approach uses proinsulin peptides to train regulatory T cells (Tregs) to suppress the autoimmune response. JDRF-funded research has also advanced the use of nanoparticles loaded with antigens to deliver tolerogenic signals directly to the immune system. These therapies aim to halt the disease with minimal side effects.

Cell Replacement and Regeneration: New Beta Cells

For individuals who have already lost most of their beta cells, immune therapy alone may not be sufficient. JDRF has supported pioneering work in stem cell-derived beta cells and encapsulation technologies. In collaboration with companies like Vertex Pharmaceuticals, JDRF-backed research has led to the development of VX-880, a stem cell-derived islet cell therapy that is now in clinical trials. The first patient treated with VX-880 achieved insulin independence, a remarkable proof of concept.

To protect transplanted cells from immune attack without lifelong immunosuppression, JDRF funds encapsulation devices that physically isolate the cells while allowing glucose and insulin to pass. The ViaCyte (now part of Vertex) PEC-Direct device is one example: a pouch implanted under the skin that contains stem cell-derived pancreatic progenitor cells. Combined with a brief course of immune suppression, this approach has shown the ability to produce C-peptide in patients.

JDRF is also exploring gene editing to create “universal donor” stem cells that evade the immune system, using CRISPR technology to delete or modify immune recognition molecules.

Combination Therapies: Maximizing Impact

No single intervention is likely to cure T1D. JDRF has championed combination therapy trials that pair immune modulation with beta cell preservation or replacement. For example, combining teplizumab with a drug that promotes beta cell regeneration (like the GLP-1 receptor agonist liraglutide) could yield synergy. Another combination pairs anti-thymocyte globulin (ATG) with granulocyte colony-stimulating factor (G-CSF) — a regimen that has shown prolonged preservation of C-peptide in new-onset patients.

The JDRF Combination Therapy Initiative has brought together academic centers, the FDA, and industry to design rational combinations and streamline regulatory pathways. This collaborative model accelerates the pace of discovery and reduces duplication of effort.

Impact on Clinical Practice: From Research to Real-World Use

The breakthroughs enabled by JDRF are already changing how T1D is managed. The approval of teplizumab marked a paradigm shift: for the first time, physicians have a tool to delay disease onset. Screening programs for islet autoantibodies are expanding, with organizations like TrialNet (supported by JDRF, NIDDK, and others) offering free screening for relatives of people with T1D. Early detection creates a window for preventive therapy.

Prevention Trials Save Lives

JDRF’s investment in prevention research has yielded multiple ongoing trials. The TrialNet Prevention Studies test agents like teplizumab, oral insulin, and hydroxychloroquine in autoantibody-positive individuals. Results from these studies will guide future preventive strategies and may eventually lead to universal screening for T1D risk.

Early Intervention and Progression Slowing

For those already diagnosed, JDRF-funded research has shown that early aggressive immune modulation can preserve residual beta cell function. A child treated with teplizumab shortly after diagnosis may maintain higher C-peptide levels for years, translating to lower insulin doses, fewer hypoglycemic episodes, and better long-term outcomes. The concept of “honeymoon” period — when some beta cell function remains — can be extended significantly.

Future Directions: Toward a Cure

JDRF’s vision extends well beyond what is currently possible. The organization is funding next-generation immune therapies, including CAR-Treg cells (chimeric antigen receptor regulatory T cells) that can home in on the pancreas and specifically suppress the autoimmune attack without affecting systemic immunity. These engineered cells hold enormous promise for targeted, durable tolerance.

Another frontier is combination immune therapy with beta cell regeneration. JDRF is supporting research into drugs that stimulate beta cell replication (such as DYRK1A inhibitors) and transcription factors that can convert other pancreatic cells into insulin-producing cells. If immune attack is first halted, then regenerated beta cells could survive and function indefinitely.

JDRF also partners with companies developing closed-loop insulin delivery systems (artificial pancreas) to improve quality of life while a biological cure is pursued. However, the ultimate goal remains full restoration of endogenous insulin production without immunosuppression.

Personalized Medicine: Tailoring Therapy to the Individual

Not all T1D patients are the same. Genetic background, age at onset, immune phenotype, and gut microbiome composition all influence disease progression and response to therapy. JDRF funds research into precision immunology, using multi-omics data to predict which treatment will work best for which patient. For example, a teenager with a high-risk HLA genotype may benefit from a different combination than a child with a single autoantibody. Smart clinical trial designs, including adaptive platform trials, will allow rapid testing of multiple arms.

Overcoming Barriers: Cost, Access, and Scalability

Even as breakthroughs emerge, JDRF recognizes the need to make therapies accessible. The organization advocates for insurance coverage of screening and preventative treatments, supports patient education, and funds implementation science to understand how to deliver new therapies in real-world settings. Teplizumab costs several hundred thousand dollars per course, and not all insurers cover it. JDRF works with policymakers and drug manufacturers to reduce costs and expand access.

Conclusion: A Future Worth Fighting for

The scientific breakthroughs enabled by JDRF in T1D immune therapy have fundamentally changed the outlook for people living with or at risk for this disease. From immune-modulating drugs that delay onset to stem cell therapies that have already restored insulin independence in a handful of patients, the progress is tangible and accelerating. JDRF’s strategic investment in foundational science, clinical trials, and collaborative networks has de-risked novel approaches and built the infrastructure for a cure. While challenges remain — cost, durability of effect, and the need for better biomarkers — the trajectory is clear. With continued support, the promise of preventing, reversing, or even curing type 1 diabetes is within reach.

For more information on JDRF’s research programs and how to get involved, visit their official site. To learn about screening for T1D risk, explore the TrialNet network. For details on teplizumab and other disease-modifying therapies, see the FDA announcement. Additional resources are available at JDRF and through the National Institute of Diabetes and Digestive and Kidney Diseases.